Clinical parameters of bi-RTI, PI+LD−, and PI+LD+ patients
| Parameters . | Bi-RTI, n = 10 . | Pl+LD−, n = 24 . | PI+LD+, n = 17 . |
|---|---|---|---|
| Age | 35.5 ± 10.4 | 37.5 ± 5.7 | 44.2 ± 9.9* |
| Sex, M/F (ratio) | 10/0 | 20/4 | 14/3 |
| CD4 | |||
| N/mm3 | 467 ± 161 | 517 ± 234 | 471 ± 225 |
| Range | 248-774 | 290-990 | 284-925 |
| CD8 | |||
| n/mm3 | 955 ± 347 | 911 ± 498 | 1235 ± 501*,† |
| Range | 538-1572 | 341-2040 | 616-2620 |
| Viral load, log10 DNA copies/mm3‡ | 3.45 ± 0.80 | 2.67 ± 0.55† | 2.49 ± 0.38† |
| Length of PI therapy, months | 0.0 ± 0.0 | 13.5 ± 3.6 | 20.7 ± 8.3* |
| CD4 increase using PI, n/mm3 | — | 229 ± 175 | 386 ± 243 |
| CD8 increase using PI, n/mm3 | — | 12 ± 484 | 508 ± 623* |
| Parameters . | Bi-RTI, n = 10 . | Pl+LD−, n = 24 . | PI+LD+, n = 17 . |
|---|---|---|---|
| Age | 35.5 ± 10.4 | 37.5 ± 5.7 | 44.2 ± 9.9* |
| Sex, M/F (ratio) | 10/0 | 20/4 | 14/3 |
| CD4 | |||
| N/mm3 | 467 ± 161 | 517 ± 234 | 471 ± 225 |
| Range | 248-774 | 290-990 | 284-925 |
| CD8 | |||
| n/mm3 | 955 ± 347 | 911 ± 498 | 1235 ± 501*,† |
| Range | 538-1572 | 341-2040 | 616-2620 |
| Viral load, log10 DNA copies/mm3‡ | 3.45 ± 0.80 | 2.67 ± 0.55† | 2.49 ± 0.38† |
| Length of PI therapy, months | 0.0 ± 0.0 | 13.5 ± 3.6 | 20.7 ± 8.3* |
| CD4 increase using PI, n/mm3 | — | 229 ± 175 | 386 ± 243 |
| CD8 increase using PI, n/mm3 | — | 12 ± 484 | 508 ± 623* |
Bi-RTI patients received ZDV plus ddI or ZDV plus ddC for 3-6 months. PI+ patients received a combination of bi-RTI and 1 PI including ZDV, ddI, d4T, 3tC, IDV, RTV, or SQV. The only difference between LD+ vs LD− regimens concerned the treatment of LD+ patients, who received RTV more frequently and ZDV less frequently (P < .02 andP < .003, respectively, for the X2test). Values are given as the mean plus or minus SD.
P < .05 vs PI+LD− group.
P < .05 vs bi-RTI group.
Amplicor HIV-1 Monitor test (Roche) was used.